Abstract Patient-derived organoids (PDOs) established from tissues from various tumor types gave the foundation of ex vivo models to screen and/or validate the activity of many cancer drug candidates. Due to their phenotypic and genotypic similarity to the tumor of which they were derived. PDOs offer results that effectively complement those obtained from more complex models. Yet. https://pipingrockers.shop/product-category/fertility/